DEPOMED, INC.Warrant Agreement • January 10th, 2001 • Depomed Inc • Services-commercial physical & biological research • California
C. The Company and EIS are executing and delivering on the date hereof a Registration Rights Agreement, in the form attached hereto as Exhibit C --------- (as amended at any time, the "Company Registration Rights Agreement"), in...Securities Purchase Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
AGREEMENT ---------Lease • April 18th, 1997 • Depomed Inc
EXHIBIT 10.10 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the "Agreement") is entered into as of this ______ day of ____________, 1997, by and between DepoMed, Inc., a California corporation (the "Company"), and ___________________, an...Indemnification Agreement • August 1st, 1997 • Depomed Inc • Services-commercial physical & biological research • California
DEPOMED, INC. ANDWarrant Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research • New York
EXHIBIT 1.1 [Form of Underwriting Agreement - Subject to Additional Review] 2,500,000 SHARES OF COMMON STOCK AND 1,250,000 REDEEMABLE WARRANTS DEPOMED, INC. UNDERWRITING AGREEMENT ----------------------Underwriting Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research • New York
AGREEMENT ---------Settlement Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research • California
DEPOMED, INC. COMMON STOCKCommon Stock Purchase Agreement • May 14th, 1998 • Depomed Inc • Services-commercial physical & biological research • California
February 20, 1998Letter Agreement • May 14th, 1998 • Depomed Inc • Services-commercial physical & biological research • New Jersey
JOINT FILING AGREEMENTJoint Filing Agreement • July 15th, 2003 • Depomed Inc • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated July 8, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, no par value per share, of Depomed, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
DEPOMED, INC. Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. Trustee INDENTURE Dated as of September 9, 2014 Senior Debt SecuritiesIndenture • September 9th, 2014 • Depomed Inc • Pharmaceutical preparations • New York
R E C I T A L S: ---------------Employment Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research • California
DEPOMED, INC. REGISTRATION RIGHTS AGREEMENT -----------------------------Registration Rights Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
STOCK PURCHASE AGREEMENT by and between BIOVAIL LABORATORIES INCORPORATEDStock Purchase Agreement • October 25th, 2002 • Depomed Inc • Pharmaceutical preparations • New York
EXHIBIT 4.5 ----------- NATIONAL SECURITIES CORPORATION As Representative of the several Underwriters 1001 Fourth Avenue Suite 2200 Seattle, Washington 98154 Ladies and Gentlemen: In order to induce National Securities Corporation, the representative...Lock-Up Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research
EXHIBIT 10.5 ------------ W I T N E S S E T H:Lease Agreement • April 18th, 1997 • Depomed Inc
BETWEEN DEPOMED, INC. ANDLicense Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
JOINT FILING AGREEMENTJoint Filing Agreement • June 3rd, 2003 • Depomed Inc • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated June 3, 2003 (the "Schedule 13G/A"), with respect to the Common Stock, no par value per share, of Depomed, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
SUBLEASE -------- THIS SUBLEASE (this "Sublease") is dated for reference purposes as of February 18, 1998, and is made by and between Cell Genesys, Inc., a Delaware corporation, ("Sublessor"), and DepoMed, Inc., a California corporation ("Sublessee")....Sublease • May 14th, 1998 • Depomed Inc • Services-commercial physical & biological research • California
Rights Agreement Dated as of July 12, 2015Rights Agreement • July 13th, 2015 • Depomed Inc • Pharmaceutical preparations • California
This Rights Agreement, dated as of July 12, 2015 (the “Agreement”), between Depomed, Inc., a California corporation (the “Company”), and Continental Stock Transfer & Trust Company (the “Rights Agent”),
R E C I T A L S: ---------------Employment Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research • California
ANDWarrant Agreement • October 6th, 1997 • Depomed Inc • Services-commercial physical & biological research • New York
EXHIBIT 1.1 1,200,000 UNITS, EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE REDEEMABLE WARRANT DEPOMED, INC. UNDERWRITING AGREEMENT ----------------------Underwriting Agreement • October 6th, 1997 • Depomed Inc • Services-commercial physical & biological research • New York
Exhibit 10.5 BASIC LEASE INFORMATION LEASE DATE: September 2, 1992 TENANT: DepoMed Systems, Inc., a California Corporation TENANTS ADDRESS: 1170 B Chess Drive Foster City, CA 94404 LANDLORD: 1170 CHESS DRIVE LIMITED PARTNERSHIP, a Texas Limited...Lease Agreement • June 17th, 1997 • Depomed Inc • Services-commercial physical & biological research
Exhibit 1.3 DEPOMED DEVELOPMENT LTD. REGISTRATION RIGHTS AGREEMENT -----------------------------Registration Rights Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
ANDRepresentative's Warrant Agreement • October 6th, 1997 • Depomed Inc • Services-commercial physical & biological research • New York
1) ELAN CORPORATION, PLC, a public limited company incorporated under the laws of Ireland, and having its registered office at Lincoln House, Lincoln Place, Dublin 2, Ireland ("Elan"); ----Funding Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • August 15th, 2018 • Assertio Therapeutics, Inc • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of , 20 (the “Effective Date”) by and between Assertio Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”).
DEPOMED, INC. 2.50% CONVERTIBLE SENIOR NOTES DUE 2021 UNDERWRITING AGREEMENTUnderwriting Agreement • September 9th, 2014 • Depomed Inc • Pharmaceutical preparations • New York
DEPOMED, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A, as Trustee First Supplemental Indenture Dated as of September 9, 2014 to Indenture Dated as of September 9, 2014 2.50% Convertible Senior Notes due 2021First Supplemental Indenture • September 9th, 2014 • Depomed Inc • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of September 9, 2014 (this “Supplemental Indenture”), between DEPOMED, INC., a California corporation, as issuer (the “Company,” as more fully set forth in Section 2.01) and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a New York banking association, as trustee (the “Trustee,” as more fully set forth in Section 2.01), supplementing the Indenture relating to “Senior Debt Securities” dated as of September 9, 2014, between the Issuer and the Trustee (the “Base Indenture” and, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
COMMON STOCK PURCHASE AGREEMENT Dated December 11, 2006 by and between DEPOMED, INC. and AZIMUTH OPPORTUNITY LTD.Common Stock Purchase Agreement • December 12th, 2006 • Depomed Inc • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 11th day of December 2006 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Depomed, Inc., a corporation organized and existing under the laws of the State of California (the “Company”).
DEPOMED, INC. CLASS B WARRANTWarrant Agreement • January 10th, 2001 • Depomed Inc • Services-commercial physical & biological research • California
AND DEPOMED, INC. ANDSubscription, Joint Development and Operating Agreement • February 18th, 2000 • Depomed Inc • Services-commercial physical & biological research • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 8th, 2008 • Depomed Inc • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT, dated as of June 27, 2008 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is among GENERAL ELECTRIC CAPITAL CORPORATION (“GECC”), in its capacity as agent for Lenders (as defined below) (together with its successors and assigns in such capacity, “Agent”), OXFORD FINANCE CORPORATION (“Oxford”), the other financial institutions who are or hereafter become parties to this Agreement as lenders (together with GECC and Oxford, collectively the “Lenders”, and each individually, a “Lender”), DEPOMED, INC., a California corporation (“Borrower”), and the other entities or persons, if any, who are or hereafter become parties to this Agreement as guarantors (each a “Guarantor” and collectively, the “Guarantors”, and together with Borrower, each a “Loan Party” and collectively, “Loan Parties”).
FORM OF ASSERTIO THERAPEUTICS, INC. AMENDED AND RESTATED MANAGEMENT CONTINUITY AGREEMENTManagement Continuity Agreement • August 15th, 2018 • Assertio Therapeutics, Inc • Pharmaceutical preparations • Delaware
This Amended and Restated Management Continuity Agreement (the “Agreement”) is effective as of , 20 (the “Effective Date”) by and between (“Employee”) and Assertio Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Employee with certain benefits described herein upon the occurrence of specific events. This Agreement amends and restates that certain Management Continuity Agreement entered into between the parties as of (referred to herein as the “Prior Agreement”).
